Telix Pharmaceuticals (OTCMKTS:TLPPF) Shares Up 5.1% – What’s Next?

Telix Pharmaceuticals Limited (OTCMKTS:TLPPF)’s share price traded up 5.1% during mid-day trading on Thursday . The stock traded as high as $11.65 and last traded at $11.65. 1,000 shares traded hands during mid-day trading, a decline of 75% from the average daily volume of 3,925 shares. The stock had previously closed at $11.0816.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating on shares of Telix Pharmaceuticals in a research note on Wednesday. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $20.00.

Telix Pharmaceuticals Price Performance

The stock’s 50-day moving average price is $10.98 and its two-hundred day moving average price is $9.78.

About Telix Pharmaceuticals

Telix Pharmaceuticals is a molecularly targeted radiopharmaceutical company specializing in the development and commercialisation of diagnostic and therapeutic products for oncology and rare diseases. The company leverages radioisotopes conjugated to disease-specific targeting agents, enabling precise imaging and treatment of cancerous lesions. Telix’s portfolio includes investigational imaging compounds, such as a gallium-68-labeled prostate cancer agent, alongside therapeutic candidates that deliver beta- or alpha-emitting isotopes directly to disease sites.

Telix’s lead diagnostic program focuses on positron emission tomography (PET) imaging for prostate cancer, designed to improve detection and staging accuracy.